Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 10/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CCND1 | P24385 | 2/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049671 | 0.83 | HTR7 (0.51) | HTR2AHTR2CHTR7MCL1CDK4 | |
| SCHEMBL13962823 | 0.83 | MCL1 (0.46) | HTR2AHTR2CMCL1CDK4CCND1 | |
| SCHEMBL13962828 | 0.83 | MCL1 (0.46) | HTR2AHTR2CMCL1CDK4CCND1 | |
| SCHEMBL8265371 | 0.83 | MCL1 (0.46) | HTR2AHTR2CMCL1CDK4CCND1 | |
| SCHEMBL13131405 | 0.82 | HTR7 (0.52) | HTR2AHTR2CHTR7MCL1CDK4 | |
| SCHEMBL78479 | 0.81 | HTR7 (0.53) | HTR2AHTR2CHTR7MCL1CDK4 | |
| SCHEMBL13783633 | 0.79 | HTR2A (0.47) | HTR2AHTR2CHTR7MCL1P2RX7 | |
| SCHEMBL31083788 | 0.79 | CDK4 (0.70) | HTR2AHTR2CCDK4CCND1GLO1 | |
| SCHEMBL3995842 | 0.79 | CDK4 (0.70) | HTR2AHTR2CCDK4CCND1GLO1 | |
| SCHEMBL2930757 | 0.79 | MCL1 (0.67) | MCL1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129538-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | HTR2A 1825/4885HTR2C 630/4885HTR7 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.